How is acquired antithrombin III (ATIII) deficiency treated?

Updated: Mar 04, 2020
  • Author: James L Harper, MD; Chief Editor: Hassan M Yaish, MD  more...
  • Print

Acquired antithrombin III deficiency is due to decreased production or increased consumption. In either case, treatment of the underlying disease and replacement of antithrombin III using antithrombin III concentrates is the common approach used. Some evidence indicates that using a supranormal target (140%) is necessary in pediatric patients who have experience trauma. In cases of venoocclusive disease, a target of 120% is used, and treatment is initiated once antithrombin III level is subnormal (< 75%).

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!